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Multiple myeloma (MM) accounts for around 15% of new cases
and 20% of deaths amongst patients diagnosed with haemato-
logical malignancy. To date, few risk factors have been robustly
conﬁrmed for MM, these include increasing age, male sex, black
race and a family history of MM.1
High body mass index (BMI) has been reported to be associated
with an increased risk of MM in several observational studies,
though questions remain regarding the aetiological relevance,
including the distribution of body fat.2 In addition to being a
potential risk factor for MM, some, but not all, studies have
suggested an association between BMI and prognosis.1,3 A recent
study has suggested the relationship between BMI and MM may
be through reduced levels of plasma adiponectin, the inﬂamma-
tory mediator secreted by adipocytes. The association was,
however, conﬁned to obese individuals providing an argument
against a direct causal link.4 Findings such as these, alongside the
conﬂicting results of previous studies into adiposity traits, high-
light the limitations of observational studies. Importantly, such
studies do not establish a causal relationship, as they cannot fully
eliminate the inﬂuence of confounding factors. Moreover, in the
context of prognostication, many studies have not explicitly
addressed the issue of reverse causation.5
Mendelian randomisation (MR) provides an attractive alterna-
tive to the traditional epidemiological study for examining
relationships between exposure and disease. MR makes use of
allelic variants, which are randomly assigned during meiosis and
are robustly associated with traits of interest, as instrumental
variables (IVs) to infer whether associations between exposure and
disease are causal. The use of these genetically deﬁned IVs as
proxies of modiﬁable exposure, avoids confounding by environ-
mental factors, can be reﬂective of life-long exposure and
circumvents reverse causality.
Genome-wide association studies (GWAS) have identiﬁed single-
nucleotide polymorphisms (SNPs) at multiple independent loci
signiﬁcantly associated with BMI, childhood obesity (CHO) and
plasma levels of adiponectin.6–8 Here we have sought to establish a
causal association between adiposity traits and MM by performing a
MR analysis using SNPs associated with body mass index (BMI), hip
circumference adjusted for BMI (HipadjBMI), waist circumference
adjusted for BMI (WCadjBMI), waist-to-hip ratio adjusted for BMI
(WHRadjBMI), CHO and plasma adiponectin levels as IVs.
We constructed genetic risk scores (GRS), to investigate the
relationship of adiposity and plasma levels of adiponectin with MM
risk, using the data from ﬁve reported MM GWASs, comprising 6 839
cases and 22 221 controls.9 We performed two-stage MR analysis to
assess the association between each adiposity trait and MM using
summary statistics from the MM GWAS, and the published effect size
of the adiposity trait. As per Burgess et al.,10 a ﬁxed-effects model
was used to calculate combined ratio estimates, β, for the effect of
each trait on MM risk. Results are summarised in Table 1.
Following calculation of combined ratio estimates, β, in three of
the ﬁve cohorts, a positive association was shown between one s.
d. in BMI (kg /m2) and MM risk, with the UK-GWAS series being
nominally signiﬁcant (Figure 1a). Meta-analysis of the data from all
ﬁve cohorts did not, however, provide evidence for a causal
association (odds ratio (OR) = 1.17, 95% conﬁdence intervals (CIs):
0.92–1.49, P= 0.19). Similarly, we found no association between
the other anthropometric traits, which report on central obesity
and MM risk, speciﬁcally—HipadjBMI, WCadjBMI, WHRadjBMI,
which had respective ORs of 0.77 (95% CI: 0.42–1.41), 0.62 (95% CI:
0.37–1.02) and 0.82 (95% CI: 0.57–1.19) (Figures 1b–d). We also
found no support for a relationship between CHO and MM risk
(OR= 0.98, 95% CI: 0.87–1.10; Figure 1e). We then evaluated the
impact of plasma levels of adiponectin on the risk of developing
MM, again observing no association (OR= 1.04, 95% CI: 0.64–1.72;
Figure 1f).
Linkage of the survival data to genotypes on three of the series
allowed the relationship between the aforementioned adiposity-
related traits and patient outcome to be examined through MR. In
meta- analyses of these data, no association between any of the
traits and either overall survival (OS) or progression-free survival
(PFS) was shown.
The results from our study contrast with some observational
epidemiological studies, which have shown a positive association
between adiposity and MM risk and mortality.1,11 A recent meta-
analysis of studies found a modest, but signiﬁcant association
between BMI and risk in prospective cohorts.11 Reported relative
risks for MM associated with obesity from these studies had OR 95%
CIs of 1.08–1.35. Over this range of effect, we had 16–97% study
power to demonstrate an association. Hence, we cannot exclude
the possibility that the null results we observed were simply a
consequence of limited study power if the true effect is marginal.
Obesity is a well-established risk factor for a number of other
solid cancers.12 By inference, it is likely a priori that obesity will also
increase MM risk. An elevated level of insulin-like growth factor 1,
associated with chronic hyperinsulinemia, stimulates cell prolif-
eration and inhibits apoptosis, therefore providing a biological
basis for obesity having a generic effect on cancer risk.13 In the
case of MM, the insulin receptor is overexpressed in MM cells and
is increased throughout normal plasma cell differentiation.14
These observations would therefore imply a causative effect of
Table 1. Results of associations of multiple myeloma (MM) risk with
adiposity traits using Mendelian randomisation
Trait Odds ratio 95% CI P-value
BMI 1.17 0.92;1.49 0.19
CHO 0.98 0.87;1.10 0.71
WHRadjBMI 0.82 0.57;1.19 0.29
WCadjBMI 0.62 0.37;1.02 0.06
HipadjBMI 0.77 0.42;1.41 0.39
Adiponectina 1.04 0.64;1.72 0.86
Abbreviations: BMI, body mass index; CHO, childhood obesity; HipadjBMI,
hip circumference adjusted for BMI; WCadjBMI, waist circumference
adjusted for BMI; WHRadjBMI, waist-to-hip ratio adjusted for BMI. Odds
ratio, 95% conﬁdence intervals (CIs) and and P-values from meta-analysis of
all cohorts, which demonstrates no signiﬁcant causative effect of traits on
MM risk. aMeta-analysis for adiponectin was conducted with 3 cohorts as
no SNPs were present in UK and USA data sets.
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obesity and ensuing hyperinsulinemia on plasma and myeloma
cell growth; a corollary of this may be increased risk of MM and
adverse patient outcome.
Our MR analysis does not suffer from the inﬂuence of recall bias
and confounding that can affect observational studies.5 Never-
theless, a central assumption in MR is that the variants used as IVs
are associated with the exposure being investigated. To ensure
this was the case, we only used SNPs associated with adiposity-
related traits at genome-wide signiﬁcance from GWAS. Further-
more, we only used the data from individuals of European descent
to limit bias from population stratiﬁcation. An additional assump-
tion is that the variants are associated with MM only through the
exposure and are not confounded by pleiotropy. We assessed the
impact of possible pleiotropism on MR estimates using both
inverse variance weighted (IVW) and MR-Egger regression tests as
per Bowden et al.15 Neither test provided evidence for pleiotropy,
with respective P-values of 0.2 and 0.71 for BMI, 0.77 and 0.65 for
CHO, 0.56 and 0.52 for HipadjBMI, 0.13 and 0.66 for WCadjBMI, 0.4
and 0.79 for WHRadjBMI, and 0.87 and 0.2 for adiponectin plasma
levels. While we found no evidence that the SNPs violated this IV
assumption, this does not exclude confounding by as yet
unidentiﬁed confounders.
In conclusion, high BMI is a plausible risk factor for MM;
however, observational studies so far have provided varied and
conﬂicting results, likely attributed to confounding and reverse
causation. Our MR study, which uses IVs to avoid such
confounding factors, provides no evidence of BMI or other tested
adiposity traits, inﬂuencing MM risk or survival. To robustly
establish a causal relationship through MR-based analyses, and
thus avoid confounding, far larger datasets will be required than
the one we have analysed. Such studies should be possible in the
future with ongoing GWASs of MM currently being undertaken.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
In the United Kingdom, Myeloma UK and Bloodwise provided principal funding.
Additional funding was provided by Cancer Research UK (C1298/A8362 supported by
Figure 1. Meta-analysis odds ratios (OR) for multiple myeloma per unit increase in genetic risk score (s.d. trait) for each adiposity trait. Shaded
boxes denote odds ratio for individual cohorts with areas proportional to the inverse variance weight of the estimate. Horizontal lines
represent 95% conﬁdence intervals (CIs) for individual cohorts. Shaded diamond represents summary ORs, computed under a ﬁxed-effects
models and diamond width gives 95% CIs. Solid vertical line represents null hypothesis (OR= 1) and dashed vertical line indicates OR from
meta-analysis. (a) BMI. (b) Waist circumference adjusted for BMI. (c) Waist-to-hip ratio adjusted for BMI. (d) Hip circumference adjusted for BMI.
(e) Childhood obesity. (f) Adiponectin levels.
Letter to the Editor
2
Blood Cancer Journal
the Bobby Moore Fund) and The Rosetrees Trust. This study made use of the
genotyping data on the 1958 Birth Cohort generated by the Wellcome Trust Sanger
Institute (http://www.wtccc.org.uk). We are grateful to all investigators who contributed
to NSCCG and GELCAPS, from which controls in the replication were drawn. We also
thank the staff of the CTRU University of Leeds and the NCRI Haematology Clinical
Studies Group. The US GWAS was supported by a grant from the National Institutes of
Health (P01CA055819). The German study was supported by the Dietmar-Hopp-
Stiftung, Germany, the German Cancer Aid (110,131), the German Federal Ministry of
Education and Research (CLIOMMICS 01ZX1309), the German Research Council (DFG;
Project SI236/8-1, SI236/9-1, ER 155/6-1 and the DFG CRU 216) and the Multiple
Myeloma Research Foundation. The patients were collected by the GMMG and DSMM
studies. The German GWAS made use of the genotyping data from the population-
based HNR study, which is supported by the Heinz Nixdorf Foundation (Germany). The
genotyping of the Illumina HumanOmni-1 Quad BeadChips of the HNR subjects was
ﬁnanced by the German Center for Neurodegenerative Disorders (DZNE), Bonn,
Germany. We are grateful to all investigators who contributed to the generation of this
data set. The German replication controls were collected by Peter Bugert, Institute of
Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg
University, German Red Cross Blood Service of Baden-Württemberg-Hessen, Mannheim,
Germany. This work was supported by research grants from the Swedish Foundation for
Strategic Research (KF10-0009), the Marianne and Marcus Wallenberg Foundation
(2010.0112), the Knut and Alice Wallenberg Foundation (2012.0193), the Swedish
Research Council (2012–1753), the Royal Swedish Academy of Science, ALF grants to
the University and Regional Laboratories (Labmedicin Skåne), the Siv-Inger and Per-Erik
Andersson Foundation, the Medical Faculty at Lund University and the Swedish Society
of Medicine. We thank Jörgen Adolfsson, Tomas Axelsson, Anna Collin, Ildikó Frigyesi,
Patrik Magnusson, Bertil Johansson, Jan Westin and Helga Ögmundsdóttir for their
assistance. We are indebted to the clinicians who contributed samples to Swedish,
Norwegian and Danish biobanks. We are indebted to the patients and other individuals
who participated in the project. This work was supported by Center for Translational
Molecular Medicine (BioCHIP), a clinical research grant from the European Hematology
Association, an EMCR Translational Research Grant, a BMBF grant from CLIOMMICS
(01ZX1309A) and FP7 grant MSCNET (LSHC-Ct-2006-037602). We thank the staff of the
HOVON, as well as patients and physicians at participating sites. In addition, we also
thank Jasper Koenders, Michael Vermeulen, André Uitterlinden and Nathalie van der
Velde for their assistance.
M Went1,2, A Sud1, PJ Law1, DC Johnson2, N Weinhold3,4,
A Försti5,6, M van Duin7, JS Mitchell1, B Chen5, R Kuiper7,
OW Stephens3, U Bertsch4,8, C Campo5, H Einsele9, WM Gregory10,
M Henrion1, J Hillengass4, P Hoffmann11,12, GH Jackson13,
O Lenive1, J Nickel4, MM Nöthen11,14, MI da Silva Filho5,
H Thomsen5, BA Walker3, A Broyl7, FE Davies3, C Langer15,
M Hansson16,17, M Kaiser2, P Sonneveld7, H Goldschmidt4,8,
K Hemminki5,6, B Nilsson16,18,19, GJ Morgan3 and RS Houlston1
1Division of Genetics and Epidemiology, The Institute of Cancer
Research, London, UK;
2Division of Molecular Pathology, The Institute of Cancer Research,
London, UK;
3Myeloma Institute for Research and Therapy, University of Arkansas
for Medical Sciences, Little Rock, AR, USA;
4Department of Internal Medicine V, University of Heidelberg,
Heidelberg, Germany;
5Molecular Genetic Epidemiology, German Cancer Research Center,
Heidelberg, Germany;
6Center for Primary Health Care Research, Lund University, Malmo,
Sweden;
7Department of Hematology, Erasmus MC Cancer Institute,
Rotterdam, The Netherlands;
8National Center for Tumor Diseases, Heidelberg, Germany;
9Department of Internal Medicine II, Division of Hematology and
Medical Oncology, University Hospital Würzburg, Würzburg,
Germany;
10Clinical Trials Research Unit, Leeds Institute of Clinical Trials
Research, University of Leeds, Leeds, UK;
11Institute of Human Genetics, University of Bonn, Bonn, Germany;
12Division of Medical Genetics, Department of Biomedicine, University
of Basel, Basel, Switzerland;
13Royal Victoria Inﬁrmary, Newcastle upon Tyne, Newcastle, UK;
14Department of Genomics, Life & Brain Center, University of Bonn,
Bonn, Germany;
15Department of Internal Medicine III, University of Ulm, Ulm,
Germany;
16Division of Hematology and Transfusion Medicine, Department of
Laboratory Medicine, Lund University, Lund, Sweden;
17Hematology Clinic, Skåne University Hospital, Lund, Sweden;
18Clinical Immunology and Transfusion Medicine, Laboratory
Medicine, Ofﬁce of Medical Services, Lund, Sweden and
19Broad Institute, 7 Cambridge Center, Cambridge, MA, USA
E-mail: richard.houlston@icr.ac.uk
REFERENCES
1 Teras LR, Kitahara CM, Birmann BM, Hartge PA, Wang SS, Robien K et al. Body size
and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J
Haematol 2014; 166: 667–676.
2 Carson KR, Bates ML, Tomasson MH. The skinny on obesity and plasma cell
myeloma: a review of the literature. Bone Marrow Transplant 2014; 49:
1009–1015.
3 Beason TS, Chang SH, Sanﬁlippo KM, Luo S, Colditz GA, Vij R et al. Inﬂuence of
body mass index on survival in veterans with multiple myeloma. Oncologist 2013;
18: 1074–1079.
4 Hofmann JN, Birmann BM, Teras LR, Pfeiffer RM, Wang Y, Albanes D et al. Low
levels of circulating adiponectin are associated with multiple myeloma risk in
overweight and obese individuals. Cancer Res 2016; 76: 1935–1941.
5 Berrigan D, Troiano RP, Graubard BI. BMI and mortality: the limits of epidemio-
logical evidence. Lancet 2016; 388: 734–736.
6 Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA et al. Novel loci
for adiponectin levels and their inﬂuence on type 2 diabetes and metabolic
traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet 2012; 8:
e1002607.
7 Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR et al. Genetic studies of
body mass index yield new insights for obesity biology. Nature 2015; 518:
197–206.
8 Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R et al.
New genetic loci link adipose and insulin biology to body fat distribution. Nature
2015; 518: 187–196.
9 Mitchell JS, Li N, Weinhold N, Forsti A, Ali M, van Duin M et al. Genome-wide
association study identiﬁes multiple susceptibility loci for multiple myeloma. Nat
Commun 2016; 7: 12050.
10 Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with
multiple genetic variants using summarized data. Genet Epidemiol 2013; 37:
658–665.
11 Wallin A, Larsson SC. Body mass index and risk of multiple myeloma: a meta-
analysis of prospective studies. Eur J Cancer 2011; 47: 1606–1615.
12 De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes 2013;
2013: 291546.
13 Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6
in cancer progression and therapeutic resistance. Tumour Biol 2016; 37:
11553–11572.
14 Sprynski AC, Hose D, Kassambara A, Vincent L, Jourdan M, Rossi JF et al. Insulin is a
potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor acti-
vation. Leukemia 2010; 24: 1940–1950.
15 Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression. Int J
Epidemiol 2015; 44: 512–525.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Letter to the Editor
3
Blood Cancer Journal
